AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02550067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LNG
Description: Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
Study NCT02550067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copper IUD
Description: Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
Study NCT02571816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2215
Description: oral
Study NCT04689061 — intervention group
Intervention type: DEVICE
Intervention: Arthrex FastThread Interference Screw
Description: The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping. The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping
Study NCT03127358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AiCure
Description: Smartphone App
Study NCT03127358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AiCure with gamification
Description: Smartphone App with gaming.
Study NCT01118377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine was supplied as film-coated tablets.
Study NCT01118377 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.
Study NCT01091454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brostallicin
Description: Given IV
Study NCT01091454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00575523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine 0,5mg is administered once intravenously immediately before starting percutaneous ethanol instillation.
Study NCT03375606 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for IV infusion
Study NCT00575523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
Study NCT02502396 — intervention group
Intervention type: OTHER
Intervention: Retrospective Chart Review
Description: Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF). Study conducted from from January 1, 2012 to November 7, 2016 at MD Anderson Cancer Center in Houston, Texas.
Study NCT03696771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NJH395
Description: Immune stimulator antibody conjugate (ISAC), consisting of a monoclonal antibody which targets HER2 conjugated to an immune-stimulatory agent
Study NCT02126878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog
Study NCT01984086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend)
Description: Salbutamol Sulphate 150mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
Study NCT01984086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend)
Description: Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
Study NCT01984086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)
Description: Salbutamol Sulphate 250mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
Study NCT01984086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Sulphate 200mcg UD-DPI Blister(1% blend)
Description: Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
Study NCT01984086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Diskus 200mcg Blister
Description: Salbutamol Diskus 200mcg will be supplied as blister strip contained within the Diskus device. Each blister contains a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
Study NCT01984086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol MDI 100mcg
Description: Salbutamol MDI 100mcg will be supplied as formulation of salbutamol sulphate (micronized) in propellant contained within the pressurised MDI device
Study NCT01984086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Sulphate UD-DPI Blister (selected from Part A)
Description: Formulation will be determined depending on the outcome of Part A.
Study NCT01984086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Sulphate 250mcg UD-DPI Blister (selected from Part A)
Description: Formulation will be determined depending on the outcome of Part A.
Study NCT01984086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Diskus 200mcg Blister without activated charcoal
Description: Formulation will be determined depending on the outcome of Part A.
Study NCT01984086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Diskus 200mcg Blister with activated charcoal
Description: Formulation will be determined depending on the outcome of Part A.
Study NCT01984086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol MDI 100mcg without activated charcoal
Description: Formulation will be determined depending on the outcome of Part A.
Study NCT01984086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol MDI 100mcg with activated charcoal
Description: Formulation will be determined depending on the outcome of Part A.
Study NCT01175317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid optimization
Description: Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
Study NCT01175317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Regimen based on expertise anaesthesist
Description: Fluid regimen based on expertise anaesthesist
Study NCT01711710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohesive Gel Breast Implant
Description: Cohesive Silicone Gel-Filled Breast Implant insert under the submuscular with axillary incision in breast augmentation mammoplasty.~Remove tissue expander and insert Cohesive Silicone Gel-Filled Breast Implant in breast reconstruction.
Study NCT02220478 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Lateral Approach Total Hip Arthroplasty
Description: All patients enrolled in the study are indicated for a total hip replacement, and will receive this replacement from the surgeon via a Posterior Lateral surgical approach.
Study NCT04738565 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic preparation
Description: The mixture of Lactobacillus rhamnosus ŁOCK 0900, Lactobacillus rhamnosus ŁOCK 0908 and Lactobacillus casei ŁOCK 0919 administered once a day at a dose of one billion for 3 months.
Study NCT04738565 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin comparable in color, texture and taste to the probiotic mixture administered once a day for 3 months.
Study NCT04275193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zishenqing
Description: Zishenqing Granule
Study NCT04275193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Granule manufactured to mimic Zishenqing(containing 10% composition)
Study NCT03443037 — intervention group
Intervention type: DRUG
Intervention: amantadine sulphate
Study NCT01305733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
Description: The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
Study NCT01305733 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline injection
Description: saline
Study NCT03118804 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Lung Tidal Distribution With EIT
Description: Changes of lung tidal distribution during SBT with mechanical ventilation were recorded by EIT can be used to predict weaning success or failure
Study NCT05339763 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiotherapy
Description: exposure of patients with rectal cancer to radiotherapy and assessment of their bowel function after surgery
Study NCT02108106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: A range of doses of AG-348 will be tested based on assessment of safety and tolerability.
Study NCT02108106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00238212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00238212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03932188 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mental Health Assessments and Computerized Cognitive Test
Description: Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
Study NCT03932188 — intervention group
Intervention type: DEVICE
Intervention: MRI scan
Description: Up to two MRI scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
Study NCT02496702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training on Interactive Modulare Tiles
Description: Training with the Interactive Modulare Tiles
Study NCT01060137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl matrix
Description: Fentanyl transdermal patch 12 - 25mcg/hr
Study NCT03458546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: All patients will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days for a total of 6 cycles. All patients will receive a fixed oral dose of one 500 microgram (μg) tablet per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses of roflumilast.
Study NCT00552097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe (plus simvastatin)
Description: oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
Study NCT00552097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (plus simvastatin)
Description: tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
Study NCT02227771 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Study NCT01314352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: Desloratadine Tablets, 5 mg
Study NCT01314352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Desloratadine Tablets, 5 mg
Study NCT00184041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine
Description: Induction I/II, consolidation I/II/III/IV and Maintenance
Study NCT04651881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: 1 Cap., single oral administration under fed condition
Study NCT04651881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: 1 Tab., single oral administration under fed condition
Study NCT04058054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KeraStat Gel
Description: Administered 0.025 gm of KeraStat Gel per subject on day 1 of the study.
Study NCT04058054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biafine
Description: Administered 0.025 gm of Biafine per subject on day 1 of the study.
Study NCT04058054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Histamine
Description: Administered 1 drop of Histamine Dihydrocl (6 mg/mL) per subject on day 1 of the study.
Study NCT04058054 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline (0.9% NaCl)
Description: Administered 1 drop of saline per subject on day 1 of the study.
Study NCT03996434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin
Description: withholding gonadotropin administration for at least 24 hours
Study NCT03996434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antagonist
Description: Cetrorelix acetate 0.25 mg
Study NCT00325286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Plus Extended- Release Carbamazepine
Description: Preliminary phase subjects receive ERC-CBZ starting dose range from 100 to 200 mg b.i.d. and further titration up to a maximum dose of 1600 mg/day done at the discretion of the investigator. Titration phase will not extend beyond 2 weeks.Open label phase subjects stabilized on lithium and ERC-CBZ therapy will enter this phase for 6 months
Study NCT04743700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocision
Description: Piezocisions with the help of piezotome , mesial and distal to a canine (in a vertical line) with the help of piezotome. These piezocisions will be performed on the buccal cortical bone only, 2-3mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle . The exact location of incision will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added and then 5mm incision is given in gingiva and overlying mucoperiosteum in a vertical line apically to expose the underlying bone.
Study NCT04743700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations
Description: Three MOPs mesial and three MOPs distal to canine(in a vertical line) with the help of minisrew implant driver (fig.2). These MOPs will be performed on the buccal cortical bone only, 2-3 mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and no flap will be raised. The exact location of first MOP will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added. The location of second MOP at 5mm apically in a vertical line and third MOP at 5 mm apically to second MOP
Study NCT03939806 — intervention group
Intervention type: DRUG
Intervention: Oxytocin
Description: To be given to Oxytocin group following the clamping of the umbilical cord
Study NCT03939806 — intervention group
Intervention type: DRUG
Intervention: Carbetocin
Description: To be given to Carbetocin group following the clamping of the umbilical cord
Study NCT01989234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP10811
Study NCT01989234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02632695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FOOTFIT
Description: Individuals with venous leg ulcers will be instructed on physical activity movements for their lower legs to be performed over six weeks while wearing a foot based activity monitor (accelerometer) that will send them motivational messages and progress reports. For those in the FOOTFIT Plus group, individuals will have the option to communicate with their wound care provider via text messages, emails or phone calls.
Study NCT04651881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: 1 Tab., single oral administration under fed condition
Study NCT04781114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS002
Description: JS002: 150mg(1mL) Q2W; Placebo 1mL Q2W.
Study NCT04781114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: JS002: 300mg(2mL) Q4W; Placebo 2mL Q4W.
Study NCT03271775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy program (group)
Description: Exercises group transmitted by physical therapist (Up to four participant in each group).
Study NCT03271775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy program (computerized exercises)
Description: Remote exercises program accompanied by a physical therapist guidance
Study NCT02515318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy program
Description: The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes, and included: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
Study NCT02515318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical standard treatment
Description: The standard medical treatment consists on:~Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones.
Study NCT03584633 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine Green
Description: The subjects will be exercising on a Nu-Step exercise machine that will exercise their arms and legs simultaneously for five-minute intervals. Every five minutes their limbs will be imaged with an ICG lymphography device to determine the plateau rate of indocyanine green dye after exercise.
Study NCT04117347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy A via the Re-Timer®
Description: Subjects will conduct light treatment in the mornings at home.
Study NCT04117347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy B via the Re-Timer®
Description: Subjects will conduct light treatment in the mornings at home.
Study NCT04117347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy C via the Re-Timer®
Description: Subjects will conduct light treatment in the mornings at home.
Study NCT00780260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strengths-based case management
Description: 5 session individual strengths-based case management; peer-involvement v. no peer involvement
Study NCT03120845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One visit RCT
Description: Root canal treatment in one vist
Study NCT03120845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post operative pain in two-visits RCT
Description: Root canal treatment in Two visits
Study NCT04329767 — intervention group
Intervention type: DEVICE
Intervention: IRIS 1.0
Description: Intuitive's IRIS 1.0 system is a software only device and service intended to create and deliver segmented image studies (3D anatomical models) based on patients computed tomography (CT) scans. It is intended as software for preoperative surgical planning, and as software for the intraoperative display of the aforementioned multidimensional digital images.
Study NCT04312022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry extract
Description: Berry extract supplement (hawthorn berry extract, tart cherry extract, bromelain)
Study NCT04312022 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (flour capsule)
Study NCT02850341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: Patients receive a pedometer with instructions how to raise their number of daily steps
Study NCT00714948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin plus sorafenib
Description: Gemcitabine 1000 mg/m 2 will be administered on days 1 and 8 and cisplatin 35 mg/m 2 will be administered on days 1 and 8. A total of six cycles of therapy will be administered at 21day intervals. Sorafenib 400 mg PO twice daily will be initiated on day 1 of cycle 1 and continued, as tolerated, until the time of disease progression or a maximum of 12 months. The total chemotherapy dose for gemcitabine and cisplatin (GC) may be modified for patients with severe obesity (e.g. body surface area (BSA) > 2.1), after consultation with the Principal Investigator.
Study NCT02709161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-time fMRI neurofeedback: Amygdala
Description: Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories